31 July 2026
31 July 2026
The eyonis LCS Software as a Medical Device uses AI to help clinicians detect and diagnose lung cancer earlier.
Participants will be randomised to two EVO756 dose arms or a placebo for 12 weeks with daily doses reaching up to 100mg.
The investment will support Resilience’s advanced manufacturing operations in Cincinnati.
The Axogen investment will be used to progress the technology into Phase II and III clinical studies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
